Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 3Breast Neoplasms 3Lymphoma, Non-Hodgkin 2Leukemia 2Triple Negative Breast Neoplasms 1Teratoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Lymphoma 1Inflammatory Breast Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Glioma 1Choriocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Cyclosporine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × pegfilgrastim × 90 days × Clear all
NCT06594939 2026-05-01

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Medical College of Wisconsin

Phase 2 Not yet recruiting
31 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡